Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis
The Protein Journal · 2023
DOI: 10.1007/s10930-023-10135-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Protein Journal, 2023. Verfasst von Shivani Thakur und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Bhilai, Sejbahar, Raipur, Chhattisgarh, 492015, India. Hauptthemen laut MEDLINE: Methionine-tRNA Ligase, Mycobacterium tuberculosis, Amino Acyl-tRNA Synthetases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 112 Literaturangaben. Gefördert von: PMRF Fellowship, Govt. of India, Science and Engineering Research Board, Indian Institute of Technology Bhilai.
Abstract (Originalsprache)
Tuberculosis caused by Mycobacterium tuberculosis (M.tb) has killed millions worldwide. Antibiotic resistance leads to the ineffectiveness of the current therapies. Aminoacyl tRNA synthetase (aaRS) class of proteins involved in protein synthesis are promising bacterial targets for developing new therapies. Here, we carried out a systematic comparative study on the aaRS sequences from M.tb and human. We listed important M.tb aaRS that could be explored as potential M.tb targets alongside the detailed conformational space analysis of methionyl-tRNA synthetase (MetRS) in apo- and substrate-bound form, which is among the proposed targets. Understanding the conformational dynamics is central to the mechanistic understanding of MetRS, as the substrate binding leads to the conformational changes causing the reaction to proceed. We performed the most complete simulation study of M.tb MetRS for 6 microseconds (2 systems × 3 runs × 1 microsecond) in the apo and substrate-bound states. Interestingly, we observed differential features, showing comparatively large dynamics for the holo simulations, whereas the apo structures became slightly compact with reduced solvent exposed area. In contrast, the ligand size decreased significantly in holo structures possibly to relax ligand conformation. Our findings correlate with experimental studies, thus validating our protocol. Adenosine monophosphate moiety of the substrate exhibited quite higher fluctuations than the methionine. His21 and Lys54 were found to be the important residues forming prominent hydrogen bond and salt-bridge interactions with the ligand. The ligand-protein affinity decreased during simulations as computed by MMGBSA analysis over the last 500 ns trajectories, which indicates the conformational changes upon ligand binding. These differential features could be further explored for designing new M.tb inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Indian Institute of Technology Bhilai, Sejbahar, Raipur, Chhattisgarh, 492015, India.
- Department of Chemistry, Indian Institute of Technology Bhilai, Sejbahar, Raipur, Chhattisgarh, 492015, India. rukmankesh@iitbhilai.ac.in.
- Department of Bioscience and Biomedical Engineering, Indian Institute of Technology Bhilai, Sejbahar, Raipur, Chhattisgarh, 492015, India. rukmankesh@iitbhilai.ac.in.
Förderung
- PMRF Fellowship, Govt. of India
- Science and Engineering Research Board
- Indian Institute of Technology Bhilai
Zitieren
APA
Thakur, S., & Mehra, R. (2023). Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis. The Protein Journal. https://doi.org/10.1007/s10930-023-10135-3
Vancouver
Thakur S, Mehra R. Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis. The Protein Journal. 2023. doi:10.1007/s10930-023-10135-3
BibTeX
@article{Thakur2023,
author = {Thakur, Shivani and Mehra, Rukmankesh},
title = {Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis},
journal = {The Protein Journal},
year = {2023},
doi = {10.1007/s10930-023-10135-3}
}
EUVIMED